Literature DB >> 17332777

Antitumor activity of dual-specific T cells and influenza virus.

A Murphy1, J A Westwood, L E Brown, M W L Teng, M Moeller, Y Xu, M J Smyth, P Hwu, P K Darcy, M H Kershaw.   

Abstract

Activation and expansion of T cells are important in disease resolution, but tumors do not usually satisfy these immune requirements. Therefore, we employed a novel strategy whereby dual-specific T cells were generated that could respond to both tumor and influenza virus, reasoning that immunization with influenza virus would activate and expand tumor-specific cells, and inhibit tumor growth. Dual-specific T cells were generated by gene modification of influenza virus-specific mouse T cells with a chimeric gene-encoding reactivity against the erbB2 tumor-associated antigen. Dual-specific T cells were demonstrated to respond against both tumor and influenza in vitro, and expanded in vitro in response to influenza to a much greater degree than in response to tumor cells. Following adoptive transfer and immunization of tumor-bearing mice with influenza virus, dual-specific T cells expanded greatly in numbers in the peritoneal cavity and spleen. This resulted in a significant increase in time of survival of mice. However, tumors were not eradicated, which may have been due to the observed poor penetration of tumor by T cells. This is the first demonstration that the potent immunogenic nature of an infectious agent can be utilized to directly impact on T-cell expansion and activity against tumor in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332777     DOI: 10.1038/sj.cgt.7701034

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  11 in total

1.  Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors.

Authors:  Gang Xin; David M Schauder; Weiqing Jing; Aimin Jiang; Nikhil S Joshi; Bryon Johnson; Weiguo Cui
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

Review 2.  Gene-engineered T cells for cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Phillip K Darcy
Journal:  Nat Rev Cancer       Date:  2013-08       Impact factor: 60.716

Review 3.  Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies.

Authors:  L A Marr; D E Gilham; J D M Campbell; A R Fraser
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

Review 4.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

Review 5.  Personal history of infections and immunotherapy: Unexpected links and possible therapeutic opportunities.

Authors:  Camille Jacqueline; Nathalie Bonnefoy; Guillaume M Charrière; Frédéric Thomas; Benjamin Roche
Journal:  Oncoimmunology       Date:  2018-06-11       Impact factor: 8.110

6.  The construction of chimeric T-Cell receptor with spacer base of modeling study of VHH and MUC1 interaction.

Authors:  Nazanin Pirooznia; Sadegh Hasannia; Majid Taghdir; Fatemeh Rahbarizadeh; Morteza Eskandani
Journal:  J Biomed Biotechnol       Date:  2011-08-22

7.  How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer.

Authors:  Inbal Daniel-Meshulam; Shlomo Ya'akobi; Chen Ankri; Cyrille J Cohen
Journal:  Front Immunol       Date:  2012-07-06       Impact factor: 7.561

Review 8.  Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.

Authors:  Donald Bastin; Scott R Walsh; Meena Al Saigh; Yonghong Wan
Journal:  Biomedicines       Date:  2016-08-24

9.  Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.

Authors:  John Maher
Journal:  ISRN Oncol       Date:  2012-12-09

Review 10.  Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.

Authors:  Carole Achard; Abera Surendran; Marie-Eve Wedge; Guy Ungerechts; John Bell; Carolina S Ilkow
Journal:  EBioMedicine       Date:  2018-04-23       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.